Do analysts rate NVO or TAK?

Novo Nordisk A/S currently has a consensus price target of $64.94, indicating a potential upside of 55.74%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novo Nordisk A/S 1 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer NVO or TAK?

In the previous week, Novo Nordisk A/S had 65 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 71 mentions for Novo Nordisk A/S and 6 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.40 beat Takeda Pharmaceutical's score of 0.32 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 31 Very Positive mention(s) 10 Positive mention(s) 15 Neutral mention(s) 8 Negative mention(s) 5 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TAK or PFE?

Pfizer has a consensus target price of $28.39, indicating a potential upside of 3.32%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19

Does the media refer more to TAK or PFE?

In the previous week, Pfizer had 26 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 32 mentions for Pfizer and 6 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.73 beat Takeda Pharmaceutical's score of 0.32 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts rate BMY or TAK?

Bristol Myers Squibb currently has a consensus price target of $66.72, indicating a potential upside of 5.00%. Given Bristol Myers Squibb's higher probable upside, equities research analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bristol Myers Squibb 1 Sell rating(s) 10 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.56 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer BMY or TAK?

In the previous week, Bristol Myers Squibb had 33 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 39 mentions for Bristol Myers Squibb and 6 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.32 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 15 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SNY or TAK?

Sanofi presently has a consensus price target of $49.50, indicating a potential upside of 16.22%. Given Sanofi's higher probable upside, equities analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 1 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.38 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer SNY or TAK?

In the previous week, Sanofi had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for Sanofi and 6 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.93 beat Takeda Pharmaceutical's score of 0.32 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GSK or TAK?

GSK presently has a consensus target price of $56.50, indicating a potential upside of 12.37%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 2 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.09 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, GSK or TAK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.36 $7.54B $3.20 15.71 Takeda Pharmaceutical $28.32B 2.11 -$1.01B $0.34 54.84

Does the media refer more to GSK or TAK?

In the previous week, GSK had 27 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 33 mentions for GSK and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.32 beat GSK's score of 0.22 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 11 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 7 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Takeda Pharmaceutical (TAK) Competitors

$18.64 -0.06 (-0.29%)

Closing price 03:59 PM Eastern

Extended Trading

$18.65 +0.00 (+0.03%)

As of 05:06 PM Eastern

Compare

TAK vs. NVO, PFE, BMY, SNY, and GSK

Should you buy Takeda Pharmaceutical stock or one of its competitors? Takeda Pharmaceutical's main competitors and comparable companies include Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), and GSK (GSK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	3.98	$15.51B	$4.09	10.19
Takeda Pharmaceutical	$28.32B	2.11	-$1.01B	$0.34	54.84

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novo Nordisk A/S has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 65 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 71 mentions for Novo Nordisk A/S and 6 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.40 beat Takeda Pharmaceutical's score of 0.32 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	31 Very Positive mention(s)	10 Positive mention(s)	15 Neutral mention(s)	8 Negative mention(s)	5 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novo Nordisk A/S has a net margin of 35.36% compared to Takeda Pharmaceutical's net margin of 3.80%. Novo Nordisk A/S's return on equity of 58.61% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	58.61%	20.91%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Novo Nordisk A/S currently has a consensus price target of $64.94, indicating a potential upside of 55.74%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.0%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Pfizer?

Takeda Pharmaceutical (NYSE:TAK) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Pfizer had 26 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 32 mentions for Pfizer and 6 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.73 beat Takeda Pharmaceutical's score of 0.32 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.11	-$1.01B	$0.34	54.84
Pfizer	$62.58B	2.50	$7.77B	$0.76	36.15

Pfizer has a net margin of 6.80% compared to Takeda Pharmaceutical's net margin of 3.80%. Pfizer's return on equity of 19.63% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Pfizer	6.80%	19.63%	8.46%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.3%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Pfizer has a consensus target price of $28.39, indicating a potential upside of 3.32%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Summary

Pfizer beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bristol Myers Squibb has a net margin of 18.87% compared to Takeda Pharmaceutical's net margin of 3.80%. Bristol Myers Squibb's return on equity of 66.90% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Bristol Myers Squibb has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Bristol Myers Squibb currently has a consensus price target of $66.72, indicating a potential upside of 5.00%. Given Bristol Myers Squibb's higher probable upside, equities research analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has higher revenue and earnings than Takeda Pharmaceutical. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.69	$7.05B	$4.54	14.00
Takeda Pharmaceutical	$28.32B	2.11	-$1.01B	$0.34	54.84

In the previous week, Bristol Myers Squibb had 33 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 39 mentions for Bristol Myers Squibb and 6 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 0.86 beat Takeda Pharmaceutical's score of 0.32 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	15 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bristol Myers Squibb beats Takeda Pharmaceutical on 17 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Sanofi presently has a consensus price target of $49.50, indicating a potential upside of 16.22%. Given Sanofi's higher probable upside, equities analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanofi has a net margin of 8.66% compared to Takeda Pharmaceutical's net margin of 3.80%. Sanofi's return on equity of 14.19% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.09	$8.84B	$1.91	22.30
Takeda Pharmaceutical	$28.32B	2.11	-$1.01B	$0.34	54.84

In the previous week, Sanofi had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 7 mentions for Sanofi and 6 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.93 beat Takeda Pharmaceutical's score of 0.32 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

GSK has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 3.80%. GSK's return on equity of 43.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.5%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. GSK pays out 55.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.36	$7.54B	$3.20	15.71
Takeda Pharmaceutical	$28.32B	2.11	-$1.01B	$0.34	54.84

In the previous week, GSK had 27 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 33 mentions for GSK and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.32 beat GSK's score of 0.22 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	11 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	7 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

GSK presently has a consensus target price of $56.50, indicating a potential upside of 12.37%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

GSK beats Takeda Pharmaceutical on 14 of the 18 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$59.74B	$12.48B	$7.19B	$22.93B
Dividend Yield	2.59%	2.63%	2.57%	3.58%
P/E Ratio	54.84	794.70	274.09	28.24
Price / Sales	2.11	961.11	697.83	18.99
Price / Cash	5.99	89.50	77.71	34.34
Price / Book	1.21	10.47	10.37	4.66
Net Income	-$1.01B	$2.84B	$3.49B	$1.07B
7 Day Performance	2.25%	-1.82%	-1.78%	-2.12%
1 Month Performance	5.67%	0.49%	-1.48%	-4.92%
1 Year Performance	23.23%	3.84%	18.20%	8.27%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	1.7637 of 5 stars	$18.65 -0.3%	N/A	+24.1%	$59.74B	$28.32B	54.84	47,000	Insider Trade
NVO Novo Nordisk A/S	4.5171 of 5 stars	$46.59 0.0%	$64.94 +39.4%	-23.7%	$208.07B	$46.80B	11.39	69,505	Trending News Analyst Revision
PFE Pfizer	2.9727 of 5 stars	$28.42 -0.1%	$28.28 -0.5%	+14.8%	$162.16B	$62.58B	37.40	75,000	Analyst Upgrade
BMY Bristol Myers Squibb	4.5144 of 5 stars	$66.85 +0.0%	$66.06 -1.2%	+37.4%	$136.49B	$48.19B	14.72	32,500	Trending News Analyst Forecast Analyst Revision
SNY Sanofi	3.7222 of 5 stars	$44.24 flat	$49.50 +11.9%	-9.1%	$107.26B	$49.35B	23.16	74,846	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Which has stronger valuation and earnings, NVO or TAK?

Do insiders and institutionals hold more shares of NVO or TAK?

Which has more risk and volatility, NVO or TAK?

Does the media prefer NVO or TAK?

Is NVO or TAK more profitable?

Do analysts rate NVO or TAK?

Is NVO or TAK a better dividend stock?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Does the media refer more to TAK or PFE?

Which has better earnings & valuation, TAK or PFE?

Is TAK or PFE more profitable?

Do insiders and institutionals hold more shares of TAK or PFE?

Is TAK or PFE a better dividend stock?

Which has more risk and volatility, TAK or PFE?

Do analysts recommend TAK or PFE?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Do institutionals and insiders believe in BMY or TAK?

Is BMY or TAK more profitable?

Which has more volatility & risk, BMY or TAK?

Do analysts rate BMY or TAK?

Is BMY or TAK a better dividend stock?

Which has stronger valuation and earnings, BMY or TAK?

Does the media prefer BMY or TAK?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Do analysts recommend SNY or TAK?

Do insiders & institutionals believe in SNY or TAK?

Is SNY or TAK more profitable?

Which has more risk and volatility, SNY or TAK?

Is SNY or TAK a better dividend stock?

Which has preferable earnings and valuation, SNY or TAK?

Does the media prefer SNY or TAK?

Summary

How does Takeda Pharmaceutical compare to GSK?

Is GSK or TAK more profitable?

Is GSK or TAK a better dividend stock?

Which has stronger earnings & valuation, GSK or TAK?

Does the media refer more to GSK or TAK?

Which has more risk and volatility, GSK or TAK?

Do analysts recommend GSK or TAK?

Do institutionals and insiders hold more shares of GSK or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools